| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Echocardiography | 34 | 2021 | 773 | 5.120 |
Why?
|
| Echocardiography, Transesophageal | 14 | 2020 | 265 | 2.710 |
Why?
|
| Osteoarthritis, Knee | 17 | 2023 | 83 | 2.700 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 15 | 2012 | 87 | 2.690 |
Why?
|
| Guideline Adherence | 12 | 2020 | 248 | 2.450 |
Why?
|
| Cardiology | 10 | 2021 | 121 | 2.340 |
Why?
|
| Endo-1,4-beta Xylanases | 6 | 2023 | 9 | 2.220 |
Why?
|
| Bacillus subtilis | 5 | 2017 | 94 | 1.930 |
Why?
|
| Practice Guidelines as Topic | 15 | 2016 | 1090 | 1.920 |
Why?
|
| Image Enhancement | 10 | 2012 | 503 | 1.640 |
Why?
|
| Cardiovascular Diseases | 12 | 2022 | 785 | 1.550 |
Why?
|
| Heart Diseases | 8 | 2018 | 266 | 1.500 |
Why?
|
| Exercise Test | 10 | 2021 | 157 | 1.470 |
Why?
|
| Image Interpretation, Computer-Assisted | 7 | 2014 | 635 | 1.330 |
Why?
|
| Knee Injuries | 6 | 2023 | 57 | 1.290 |
Why?
|
| Magnetic Resonance Imaging | 26 | 2023 | 3562 | 1.280 |
Why?
|
| Ventricular Dysfunction, Left | 10 | 2007 | 264 | 1.250 |
Why?
|
| American Heart Association | 6 | 2020 | 112 | 1.230 |
Why?
|
| Radiology | 8 | 2017 | 209 | 1.150 |
Why?
|
| Knee Joint | 11 | 2020 | 174 | 1.120 |
Why?
|
| Inpatients | 2 | 2021 | 361 | 1.070 |
Why?
|
| Temperature | 5 | 2024 | 436 | 1.050 |
Why?
|
| Algorithms | 8 | 2014 | 1974 | 1.020 |
Why?
|
| Societies, Medical | 11 | 2017 | 647 | 1.020 |
Why?
|
| Cardiac Imaging Techniques | 4 | 2016 | 23 | 0.980 |
Why?
|
| Peripheral Vascular Diseases | 4 | 2009 | 56 | 0.980 |
Why?
|
| Receptors, G-Protein-Coupled | 4 | 2018 | 172 | 0.960 |
Why?
|
| Humans | 125 | 2023 | 96382 | 0.930 |
Why?
|
| Coronary Artery Disease | 8 | 2012 | 378 | 0.880 |
Why?
|
| Heart | 5 | 2009 | 526 | 0.860 |
Why?
|
| Syncope | 2 | 2021 | 31 | 0.850 |
Why?
|
| Electrocardiography | 5 | 2018 | 522 | 0.840 |
Why?
|
| Practice Patterns, Physicians' | 7 | 2021 | 649 | 0.830 |
Why?
|
| Saccharum | 2 | 2023 | 2 | 0.800 |
Why?
|
| Myocardial Perfusion Imaging | 5 | 2012 | 39 | 0.790 |
Why?
|
| Erectile Dysfunction | 3 | 2009 | 81 | 0.740 |
Why?
|
| Myocardial Ischemia | 5 | 2008 | 142 | 0.740 |
Why?
|
| Diagnostic Imaging | 7 | 2017 | 460 | 0.720 |
Why?
|
| Brain | 5 | 2019 | 2415 | 0.720 |
Why?
|
| Pattern Recognition, Automated | 4 | 2014 | 218 | 0.700 |
Why?
|
| Echocardiography, Stress | 2 | 2012 | 15 | 0.690 |
Why?
|
| Magnetic Resonance Imaging, Cine | 5 | 2020 | 150 | 0.690 |
Why?
|
| Radiography | 7 | 2017 | 756 | 0.640 |
Why?
|
| Heart Murmurs | 1 | 2020 | 6 | 0.640 |
Why?
|
| Cartilage, Articular | 5 | 2020 | 83 | 0.630 |
Why?
|
| Mutagenesis, Site-Directed | 5 | 2016 | 273 | 0.620 |
Why?
|
| Protein Multimerization | 4 | 2016 | 191 | 0.620 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 60 | 0.620 |
Why?
|
| Synovitis | 4 | 2020 | 17 | 0.610 |
Why?
|
| Electronic Health Records | 2 | 2021 | 412 | 0.610 |
Why?
|
| Aged | 44 | 2021 | 21309 | 0.610 |
Why?
|
| Contrast Media | 6 | 2017 | 1006 | 0.610 |
Why?
|
| Menisci, Tibial | 4 | 2023 | 30 | 0.610 |
Why?
|
| Internship and Residency | 2 | 2021 | 1104 | 0.600 |
Why?
|
| Advisory Committees | 3 | 2015 | 94 | 0.590 |
Why?
|
| Diazomethane | 1 | 2018 | 5 | 0.580 |
Why?
|
| Sensitivity and Specificity | 15 | 2012 | 1934 | 0.570 |
Why?
|
| Disease Progression | 11 | 2020 | 1586 | 0.560 |
Why?
|
| United States | 29 | 2021 | 7976 | 0.560 |
Why?
|
| Unnecessary Procedures | 3 | 2021 | 43 | 0.560 |
Why?
|
| Coronary Disease | 2 | 2010 | 225 | 0.550 |
Why?
|
| Quality of Health Care | 2 | 2014 | 386 | 0.550 |
Why?
|
| Enzyme Stability | 6 | 2024 | 47 | 0.540 |
Why?
|
| Middle Aged | 50 | 2021 | 28794 | 0.520 |
Why?
|
| Pandemics | 2 | 2021 | 905 | 0.520 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.500 |
Why?
|
| Cardiomyopathies | 4 | 2020 | 311 | 0.490 |
Why?
|
| Medicare | 1 | 2020 | 463 | 0.490 |
Why?
|
| Arthralgia | 2 | 2013 | 43 | 0.490 |
Why?
|
| Curriculum | 2 | 2017 | 615 | 0.490 |
Why?
|
| Ischemic Attack, Transient | 3 | 2008 | 193 | 0.490 |
Why?
|
| Radiologists | 1 | 2017 | 58 | 0.490 |
Why?
|
| Academic Medical Centers | 2 | 2009 | 408 | 0.480 |
Why?
|
| Reproducibility of Results | 15 | 2014 | 2764 | 0.480 |
Why?
|
| Preoperative Care | 3 | 2021 | 415 | 0.470 |
Why?
|
| Heart Ventricles | 4 | 2019 | 662 | 0.460 |
Why?
|
| Male | 52 | 2021 | 46116 | 0.460 |
Why?
|
| Receptor, Serotonin, 5-HT2C | 1 | 2015 | 2 | 0.450 |
Why?
|
| Myocardium | 3 | 2009 | 574 | 0.450 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 342 | 0.440 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 338 | 0.430 |
Why?
|
| Prevalence | 7 | 2020 | 1362 | 0.430 |
Why?
|
| Alkalies | 1 | 2014 | 10 | 0.430 |
Why?
|
| Thoracic Surgery | 2 | 2012 | 68 | 0.420 |
Why?
|
| Patient Safety | 1 | 2017 | 229 | 0.420 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 106 | 0.420 |
Why?
|
| Directed Molecular Evolution | 1 | 2014 | 25 | 0.420 |
Why?
|
| Fluorescence Resonance Energy Transfer | 3 | 2015 | 101 | 0.410 |
Why?
|
| Bone Marrow | 5 | 2020 | 415 | 0.410 |
Why?
|
| Xylans | 2 | 2024 | 3 | 0.410 |
Why?
|
| Femoral Neck Fractures | 1 | 2013 | 11 | 0.410 |
Why?
|
| Coronary Circulation | 4 | 2007 | 97 | 0.410 |
Why?
|
| Nuclear Medicine | 3 | 2008 | 12 | 0.400 |
Why?
|
| Acute Pain | 1 | 2013 | 19 | 0.400 |
Why?
|
| Predictive Value of Tests | 9 | 2021 | 1759 | 0.400 |
Why?
|
| Cardiac Catheterization | 2 | 2012 | 303 | 0.390 |
Why?
|
| Female | 51 | 2021 | 50528 | 0.390 |
Why?
|
| Stroke | 3 | 2008 | 1140 | 0.370 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2003 | 45 | 0.370 |
Why?
|
| Health Services Misuse | 1 | 2012 | 20 | 0.370 |
Why?
|
| Risk Factors | 19 | 2020 | 6120 | 0.360 |
Why?
|
| Protein Engineering | 1 | 2013 | 154 | 0.360 |
Why?
|
| Orthopedics | 1 | 2013 | 135 | 0.360 |
Why?
|
| Health Policy | 1 | 2014 | 214 | 0.350 |
Why?
|
| Recombinant Proteins | 4 | 2024 | 988 | 0.350 |
Why?
|
| Prognosis | 9 | 2023 | 4041 | 0.340 |
Why?
|
| Blood Pressure | 3 | 2010 | 900 | 0.330 |
Why?
|
| Risk Assessment | 11 | 2021 | 2528 | 0.330 |
Why?
|
| Exercise | 2 | 2019 | 373 | 0.320 |
Why?
|
| Radiopharmaceuticals | 4 | 2020 | 214 | 0.310 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2011 | 108 | 0.310 |
Why?
|
| Hot Temperature | 2 | 2013 | 227 | 0.310 |
Why?
|
| Prospective Studies | 9 | 2021 | 4742 | 0.300 |
Why?
|
| Case-Control Studies | 7 | 2023 | 1975 | 0.300 |
Why?
|
| Heart Rate | 2 | 2010 | 528 | 0.300 |
Why?
|
| Utilization Review | 3 | 2020 | 23 | 0.300 |
Why?
|
| Ventricular Function, Right | 1 | 2010 | 143 | 0.300 |
Why?
|
| Logistic Models | 8 | 2014 | 1270 | 0.290 |
Why?
|
| Ankle | 1 | 2009 | 21 | 0.290 |
Why?
|
| Brachial Artery | 1 | 2009 | 37 | 0.290 |
Why?
|
| Coronary Angiography | 2 | 2012 | 236 | 0.290 |
Why?
|
| Blood Pressure Determination | 1 | 2009 | 71 | 0.290 |
Why?
|
| Arthroplasty, Replacement, Knee | 2 | 2021 | 116 | 0.280 |
Why?
|
| Embolism | 1 | 2008 | 32 | 0.280 |
Why?
|
| Heart Atria | 2 | 2007 | 250 | 0.280 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2007 | 111 | 0.280 |
Why?
|
| Internet | 1 | 2011 | 352 | 0.280 |
Why?
|
| HEK293 Cells | 5 | 2018 | 706 | 0.280 |
Why?
|
| Clinical Competence | 4 | 2021 | 838 | 0.270 |
Why?
|
| Community Health Centers | 1 | 2009 | 119 | 0.270 |
Why?
|
| Patient Selection | 2 | 2010 | 714 | 0.270 |
Why?
|
| Mutation | 2 | 2017 | 4325 | 0.270 |
Why?
|
| Joint Instability | 2 | 2019 | 100 | 0.270 |
Why?
|
| Ambulatory Care | 1 | 2009 | 199 | 0.270 |
Why?
|
| Organotechnetium Compounds | 2 | 2007 | 10 | 0.270 |
Why?
|
| Pulmonary Embolism | 2 | 2008 | 233 | 0.270 |
Why?
|
| Organophosphorus Compounds | 2 | 2007 | 46 | 0.260 |
Why?
|
| Carotid Arteries | 1 | 2008 | 132 | 0.260 |
Why?
|
| Tibial Meniscus Injuries | 2 | 2019 | 21 | 0.260 |
Why?
|
| Documentation | 2 | 2021 | 104 | 0.260 |
Why?
|
| Bacterial Proteins | 1 | 2013 | 893 | 0.260 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1118 | 0.260 |
Why?
|
| Surveys and Questionnaires | 6 | 2019 | 2951 | 0.250 |
Why?
|
| Glycoside Hydrolases | 2 | 2017 | 14 | 0.250 |
Why?
|
| Thrombosis | 2 | 2007 | 315 | 0.250 |
Why?
|
| Protein Structure, Secondary | 3 | 2017 | 340 | 0.250 |
Why?
|
| Endocardium | 2 | 2004 | 81 | 0.250 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 2006 | 5 | 0.240 |
Why?
|
| Multivariate Analysis | 5 | 2007 | 1007 | 0.240 |
Why?
|
| Myocardial Stunning | 1 | 2006 | 10 | 0.240 |
Why?
|
| Hospitalization | 1 | 2012 | 963 | 0.240 |
Why?
|
| Time Factors | 10 | 2019 | 5524 | 0.230 |
Why?
|
| Arterio-Arterial Fistula | 1 | 2006 | 6 | 0.230 |
Why?
|
| Myocardial Infarction | 3 | 2021 | 387 | 0.230 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2006 | 43 | 0.220 |
Why?
|
| Hypertension | 2 | 2010 | 763 | 0.220 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2011 | 178 | 0.220 |
Why?
|
| Hydrolysis | 2 | 2023 | 142 | 0.220 |
Why?
|
| Ventricular Function, Left | 3 | 2021 | 533 | 0.220 |
Why?
|
| Aspergillus nidulans | 1 | 2024 | 2 | 0.220 |
Why?
|
| Adult | 19 | 2021 | 28968 | 0.220 |
Why?
|
| Acetylesterase | 1 | 2024 | 3 | 0.220 |
Why?
|
| Environmental Monitoring | 1 | 2025 | 93 | 0.210 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2012 | 1283 | 0.210 |
Why?
|
| Phospholipases A | 1 | 2004 | 46 | 0.210 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 107 | 0.210 |
Why?
|
| Anemia, Hemolytic | 2 | 2004 | 17 | 0.210 |
Why?
|
| Severity of Illness Index | 5 | 2014 | 1973 | 0.210 |
Why?
|
| Gene Expression | 3 | 2024 | 1313 | 0.210 |
Why?
|
| Conservation of Natural Resources | 1 | 2025 | 101 | 0.210 |
Why?
|
| Liposomes | 1 | 2004 | 100 | 0.210 |
Why?
|
| Vascular Surgical Procedures | 1 | 2005 | 161 | 0.210 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2004 | 19 | 0.210 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2004 | 6 | 0.210 |
Why?
|
| Brain Ischemia | 1 | 2008 | 414 | 0.210 |
Why?
|
| Aortic Diseases | 1 | 2004 | 88 | 0.200 |
Why?
|
| Education, Medical, Graduate | 2 | 2021 | 437 | 0.200 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2004 | 27 | 0.200 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 7277 | 0.200 |
Why?
|
| Models, Molecular | 4 | 2016 | 1371 | 0.200 |
Why?
|
| Thallium | 1 | 2003 | 5 | 0.200 |
Why?
|
| Ischemia | 1 | 2005 | 259 | 0.200 |
Why?
|
| Retrospective Studies | 11 | 2021 | 10719 | 0.200 |
Why?
|
| Mass Screening | 1 | 2009 | 736 | 0.200 |
Why?
|
| Aortic Valve Stenosis | 1 | 2005 | 153 | 0.200 |
Why?
|
| Pulmonary Artery | 1 | 2006 | 337 | 0.200 |
Why?
|
| Pheochromocytoma | 1 | 2004 | 53 | 0.200 |
Why?
|
| Point-of-Care Systems | 2 | 2020 | 153 | 0.200 |
Why?
|
| Bone Density | 2 | 2017 | 246 | 0.200 |
Why?
|
| Glycomics | 1 | 2023 | 3 | 0.190 |
Why?
|
| Glucuronates | 1 | 2023 | 22 | 0.190 |
Why?
|
| Xylose | 1 | 2023 | 10 | 0.190 |
Why?
|
| Radionuclide Imaging | 2 | 2016 | 183 | 0.190 |
Why?
|
| Lysine | 1 | 2004 | 181 | 0.190 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2004 | 84 | 0.190 |
Why?
|
| Schools, Nursing | 1 | 2002 | 1 | 0.190 |
Why?
|
| Oligosaccharides | 1 | 2023 | 26 | 0.190 |
Why?
|
| Perioperative Nursing | 1 | 2002 | 2 | 0.190 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2023 | 45 | 0.190 |
Why?
|
| Heart Neoplasms | 2 | 2019 | 52 | 0.190 |
Why?
|
| Inservice Training | 1 | 2002 | 37 | 0.190 |
Why?
|
| Angina Pectoris | 1 | 2002 | 18 | 0.190 |
Why?
|
| Biodiversity | 1 | 2025 | 245 | 0.190 |
Why?
|
| Chlorides | 1 | 2023 | 102 | 0.180 |
Why?
|
| Mitral Valve | 2 | 2004 | 227 | 0.180 |
Why?
|
| Cardiovascular System | 1 | 2022 | 52 | 0.180 |
Why?
|
| Primary Health Care | 3 | 2022 | 389 | 0.180 |
Why?
|
| Robotics | 1 | 2025 | 270 | 0.180 |
Why?
|
| Coronary Vessels | 1 | 2003 | 176 | 0.180 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 399 | 0.170 |
Why?
|
| Hospitals | 2 | 2021 | 334 | 0.170 |
Why?
|
| Age Distribution | 3 | 2010 | 208 | 0.170 |
Why?
|
| Laboratories | 1 | 2021 | 47 | 0.170 |
Why?
|
| Abdomen | 1 | 2021 | 119 | 0.170 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2001 | 20 | 0.170 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2001 | 41 | 0.170 |
Why?
|
| Receptors, Cell Surface | 2 | 2013 | 291 | 0.160 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2001 | 98 | 0.160 |
Why?
|
| Family Practice | 1 | 2001 | 72 | 0.160 |
Why?
|
| Physical Examination | 2 | 2020 | 148 | 0.160 |
Why?
|
| Age Factors | 5 | 2017 | 1957 | 0.160 |
Why?
|
| Data Collection | 3 | 2011 | 375 | 0.160 |
Why?
|
| Sarcoidosis | 1 | 2020 | 93 | 0.150 |
Why?
|
| Periodicals as Topic | 2 | 2012 | 168 | 0.150 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2020 | 146 | 0.150 |
Why?
|
| Calcium | 1 | 2004 | 1186 | 0.150 |
Why?
|
| Mobile Applications | 1 | 2021 | 80 | 0.150 |
Why?
|
| Posterior Cruciate Ligament | 1 | 2019 | 10 | 0.150 |
Why?
|
| Angiography | 2 | 2012 | 194 | 0.150 |
Why?
|
| Data Interpretation, Statistical | 2 | 2011 | 312 | 0.150 |
Why?
|
| Hip Joint | 1 | 2019 | 57 | 0.150 |
Why?
|
| Neurobiology | 1 | 2019 | 11 | 0.150 |
Why?
|
| Atropine | 2 | 2016 | 53 | 0.150 |
Why?
|
| Ligaments, Articular | 1 | 2019 | 40 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2017 | 2640 | 0.150 |
Why?
|
| Accelerometry | 1 | 2019 | 49 | 0.150 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2021 | 102 | 0.150 |
Why?
|
| Synovial Membrane | 1 | 2019 | 33 | 0.150 |
Why?
|
| Radiation Protection | 2 | 2016 | 26 | 0.150 |
Why?
|
| Brain Chemistry | 1 | 2019 | 110 | 0.150 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 2 | 2009 | 11 | 0.140 |
Why?
|
| Absorptiometry, Photon | 2 | 2017 | 115 | 0.140 |
Why?
|
| Receptors, Neurokinin-1 | 1 | 2018 | 8 | 0.140 |
Why?
|
| Hospitals, University | 2 | 2010 | 192 | 0.140 |
Why?
|
| Nutrition Surveys | 1 | 2019 | 130 | 0.140 |
Why?
|
| Anterior Cruciate Ligament | 1 | 2019 | 49 | 0.140 |
Why?
|
| Myelin Sheath | 1 | 2019 | 69 | 0.140 |
Why?
|
| Muscarinic Antagonists | 2 | 2016 | 59 | 0.140 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 180 | 0.140 |
Why?
|
| Substance P | 1 | 2018 | 61 | 0.140 |
Why?
|
| Tibia | 2 | 2016 | 81 | 0.140 |
Why?
|
| Walking | 1 | 2019 | 109 | 0.140 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 353 | 0.140 |
Why?
|
| Chromatography, Liquid | 1 | 2018 | 102 | 0.140 |
Why?
|
| Biomarkers | 2 | 2021 | 1977 | 0.140 |
Why?
|
| Iron | 1 | 2019 | 176 | 0.140 |
Why?
|
| Cell Membrane | 2 | 2018 | 663 | 0.140 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2018 | 106 | 0.140 |
Why?
|
| Postoperative Complications | 4 | 2021 | 2647 | 0.140 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 301 | 0.140 |
Why?
|
| Neuroimaging | 1 | 2019 | 140 | 0.130 |
Why?
|
| Receptor, Muscarinic M3 | 2 | 2015 | 11 | 0.130 |
Why?
|
| Ascomycota | 1 | 2017 | 17 | 0.130 |
Why?
|
| Databases, Factual | 5 | 2021 | 1069 | 0.130 |
Why?
|
| Pichia | 2 | 2017 | 33 | 0.130 |
Why?
|
| Longitudinal Studies | 5 | 2020 | 1235 | 0.130 |
Why?
|
| Sacroiliitis | 1 | 2017 | 4 | 0.130 |
Why?
|
| Spondylarthropathies | 1 | 2017 | 4 | 0.130 |
Why?
|
| Incidence | 4 | 2016 | 1741 | 0.130 |
Why?
|
| Stroke Volume | 3 | 2021 | 453 | 0.130 |
Why?
|
| Ligands | 1 | 2018 | 484 | 0.130 |
Why?
|
| Communication | 1 | 2021 | 450 | 0.130 |
Why?
|
| Arthritis, Infectious | 1 | 2017 | 19 | 0.130 |
Why?
|
| Soft Tissue Infections | 1 | 2017 | 28 | 0.130 |
Why?
|
| Osteomyelitis | 1 | 2017 | 57 | 0.130 |
Why?
|
| Fungal Proteins | 1 | 2017 | 148 | 0.130 |
Why?
|
| Back Pain | 1 | 2017 | 76 | 0.120 |
Why?
|
| Risk Management | 1 | 2017 | 43 | 0.120 |
Why?
|
| Value-Based Purchasing | 1 | 2016 | 5 | 0.120 |
Why?
|
| Regional Health Planning | 1 | 2016 | 12 | 0.120 |
Why?
|
| Hydrogen Bonding | 1 | 2017 | 160 | 0.120 |
Why?
|
| Models, Theoretical | 1 | 2019 | 500 | 0.120 |
Why?
|
| Bone Malalignment | 1 | 2016 | 6 | 0.120 |
Why?
|
| Perfusion | 2 | 2009 | 269 | 0.120 |
Why?
|
| Glycosylation | 2 | 2015 | 137 | 0.120 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2017 | 102 | 0.120 |
Why?
|
| Illinois | 3 | 2008 | 517 | 0.120 |
Why?
|
| Receptor, Muscarinic M1 | 1 | 2016 | 2 | 0.120 |
Why?
|
| Pirenzepine | 1 | 2016 | 6 | 0.120 |
Why?
|
| Bacillus licheniformis | 1 | 2016 | 1 | 0.120 |
Why?
|
| Galactans | 1 | 2016 | 3 | 0.120 |
Why?
|
| Adipose Tissue | 1 | 2019 | 279 | 0.120 |
Why?
|
| Heart Failure | 2 | 2011 | 1460 | 0.120 |
Why?
|
| Biomass | 1 | 2016 | 46 | 0.120 |
Why?
|
| Musculoskeletal Diseases | 1 | 2016 | 37 | 0.120 |
Why?
|
| Trastuzumab | 1 | 2016 | 92 | 0.110 |
Why?
|
| Osteoporosis | 1 | 2017 | 133 | 0.110 |
Why?
|
| Muscle, Skeletal | 1 | 2019 | 515 | 0.110 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2015 | 6 | 0.110 |
Why?
|
| Foot Injuries | 1 | 2015 | 13 | 0.110 |
Why?
|
| Acute Disease | 4 | 2015 | 850 | 0.110 |
Why?
|
| Simulation Training | 1 | 2017 | 114 | 0.110 |
Why?
|
| Ankle Fractures | 1 | 2015 | 8 | 0.110 |
Why?
|
| Aftercare | 1 | 2016 | 91 | 0.110 |
Why?
|
| Protein Structure, Quaternary | 1 | 2015 | 105 | 0.110 |
Why?
|
| Endoscopy | 1 | 2019 | 378 | 0.110 |
Why?
|
| Protein Transport | 2 | 2015 | 441 | 0.110 |
Why?
|
| Diagnosis, Differential | 4 | 2008 | 1549 | 0.110 |
Why?
|
| Ankle Injuries | 1 | 2015 | 36 | 0.110 |
Why?
|
| Sex Factors | 2 | 2010 | 1135 | 0.110 |
Why?
|
| Chicago | 2 | 2009 | 1488 | 0.110 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2017 | 311 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2021 | 3157 | 0.100 |
Why?
|
| Escherichia coli | 2 | 2016 | 569 | 0.100 |
Why?
|
| Green Fluorescent Proteins | 1 | 2015 | 309 | 0.100 |
Why?
|
| Chronic Pain | 1 | 2017 | 199 | 0.100 |
Why?
|
| Follow-Up Studies | 5 | 2016 | 3969 | 0.100 |
Why?
|
| Diagnostic Errors | 1 | 2014 | 161 | 0.100 |
Why?
|
| Odds Ratio | 2 | 2020 | 723 | 0.100 |
Why?
|
| Cyclopropanes | 1 | 2013 | 26 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 554 | 0.100 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2014 | 129 | 0.100 |
Why?
|
| Molecular Probe Techniques | 1 | 2013 | 9 | 0.100 |
Why?
|
| Mutagenesis | 1 | 2013 | 194 | 0.100 |
Why?
|
| Biotinylation | 1 | 2013 | 43 | 0.090 |
Why?
|
| Butyrates | 1 | 2013 | 60 | 0.090 |
Why?
|
| Risk | 2 | 2020 | 659 | 0.090 |
Why?
|
| Thiazoles | 1 | 2013 | 126 | 0.090 |
Why?
|
| Robotic Surgical Procedures | 1 | 2019 | 390 | 0.090 |
Why?
|
| Receptors, Neuropeptide | 1 | 2012 | 9 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 893 | 0.090 |
Why?
|
| Microspheres | 2 | 2002 | 90 | 0.090 |
Why?
|
| Calibration | 1 | 2012 | 110 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2016 | 413 | 0.090 |
Why?
|
| Neuropeptides | 1 | 2012 | 113 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 435 | 0.090 |
Why?
|
| Acetamides | 1 | 2011 | 26 | 0.080 |
Why?
|
| Models, Cardiovascular | 1 | 2012 | 96 | 0.080 |
Why?
|
| Evidence-Based Practice | 1 | 2011 | 53 | 0.080 |
Why?
|
| MAP Kinase Signaling System | 1 | 2012 | 210 | 0.080 |
Why?
|
| Diagnostic Test Approval | 1 | 2010 | 1 | 0.080 |
Why?
|
| Forecasting | 2 | 2019 | 292 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2014 | 792 | 0.080 |
Why?
|
| General Practitioners | 1 | 2010 | 10 | 0.080 |
Why?
|
| Physical Exertion | 1 | 2010 | 39 | 0.080 |
Why?
|
| Fatty Acids | 1 | 2011 | 145 | 0.080 |
Why?
|
| Sample Size | 1 | 2010 | 130 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2014 | 510 | 0.080 |
Why?
|
| Quality Control | 1 | 2010 | 125 | 0.080 |
Why?
|
| Fractures, Bone | 1 | 2012 | 155 | 0.080 |
Why?
|
| Cloning, Molecular | 2 | 2024 | 581 | 0.080 |
Why?
|
| Substrate Specificity | 2 | 2024 | 368 | 0.080 |
Why?
|
| Health Care Costs | 1 | 2012 | 252 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 400 | 0.080 |
Why?
|
| Phantoms, Imaging | 1 | 2012 | 485 | 0.070 |
Why?
|
| Reference Values | 1 | 2010 | 610 | 0.070 |
Why?
|
| Canada | 2 | 2022 | 202 | 0.070 |
Why?
|
| Prone Position | 1 | 2009 | 63 | 0.070 |
Why?
|
| Peptides | 1 | 2012 | 664 | 0.070 |
Why?
|
| Observer Variation | 2 | 2014 | 573 | 0.070 |
Why?
|
| Microbubbles | 1 | 2008 | 40 | 0.070 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2008 | 85 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2010 | 364 | 0.070 |
Why?
|
| Tomography, Spiral Computed | 1 | 2008 | 75 | 0.070 |
Why?
|
| Binding Sites | 2 | 2013 | 1145 | 0.070 |
Why?
|
| Embolectomy | 1 | 2007 | 6 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2011 | 379 | 0.060 |
Why?
|
| Kinetics | 2 | 2024 | 1474 | 0.060 |
Why?
|
| Gadolinium DTPA | 1 | 2008 | 239 | 0.060 |
Why?
|
| False Positive Reactions | 1 | 2006 | 213 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2006 | 162 | 0.060 |
Why?
|
| ROC Curve | 1 | 2008 | 789 | 0.060 |
Why?
|
| Intermittent Claudication | 1 | 2005 | 19 | 0.060 |
Why?
|
| Crystallography | 1 | 2005 | 46 | 0.060 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2005 | 8 | 0.060 |
Why?
|
| Esophageal Perforation | 1 | 2005 | 18 | 0.060 |
Why?
|
| Protein Denaturation | 1 | 2005 | 110 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 581 | 0.060 |
Why?
|
| Statistics as Topic | 1 | 2006 | 230 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2016 | 9526 | 0.060 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2005 | 61 | 0.060 |
Why?
|
| Catalysis | 1 | 2005 | 216 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2005 | 1525 | 0.060 |
Why?
|
| Aneurysm | 1 | 2005 | 59 | 0.060 |
Why?
|
| Comorbidity | 2 | 2006 | 1027 | 0.060 |
Why?
|
| Referral and Consultation | 1 | 2008 | 400 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2006 | 227 | 0.060 |
Why?
|
| Probability | 1 | 2006 | 354 | 0.050 |
Why?
|
| Crotalid Venoms | 1 | 2004 | 3 | 0.050 |
Why?
|
| Cerebrovascular Disorders | 1 | 2005 | 140 | 0.050 |
Why?
|
| Vascular Diseases | 1 | 2005 | 120 | 0.050 |
Why?
|
| Radiation Dosage | 2 | 2016 | 231 | 0.050 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2004 | 24 | 0.050 |
Why?
|
| Circular Dichroism | 1 | 2004 | 118 | 0.050 |
Why?
|
| Gallstones | 1 | 2004 | 21 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2025 | 157 | 0.050 |
Why?
|
| Molecular Weight | 1 | 2024 | 280 | 0.050 |
Why?
|
| Ultrasonography | 2 | 2017 | 709 | 0.050 |
Why?
|
| Dimerization | 1 | 2004 | 149 | 0.050 |
Why?
|
| Aorta | 1 | 2005 | 275 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2005 | 580 | 0.050 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2004 | 7 | 0.050 |
Why?
|
| Extremities | 1 | 2005 | 170 | 0.050 |
Why?
|
| Surface-Active Agents | 1 | 2004 | 58 | 0.050 |
Why?
|
| Creatine Kinase | 1 | 2004 | 51 | 0.050 |
Why?
|
| Myxoma | 1 | 2004 | 28 | 0.050 |
Why?
|
| Tryptophan | 1 | 2004 | 106 | 0.050 |
Why?
|
| Myocardial Reperfusion | 1 | 2004 | 25 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 212 | 0.050 |
Why?
|
| Heart Valve Prosthesis | 1 | 2004 | 95 | 0.050 |
Why?
|
| Smoking | 1 | 2007 | 669 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2024 | 484 | 0.050 |
Why?
|
| Diabetes Mellitus | 2 | 2007 | 800 | 0.050 |
Why?
|
| Rest | 1 | 2003 | 51 | 0.050 |
Why?
|
| Glucuronosyltransferase | 1 | 2004 | 178 | 0.050 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 464 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2004 | 272 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2005 | 906 | 0.050 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2004 | 111 | 0.050 |
Why?
|
| Blood Flow Velocity | 1 | 2003 | 179 | 0.050 |
Why?
|
| Protein Conformation | 1 | 2005 | 913 | 0.050 |
Why?
|
| Atherosclerosis | 1 | 2005 | 261 | 0.050 |
Why?
|
| Pulmonary Veins | 1 | 2004 | 118 | 0.050 |
Why?
|
| California | 1 | 2002 | 162 | 0.050 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2005 | 188 | 0.050 |
Why?
|
| Microcirculation | 1 | 2002 | 101 | 0.050 |
Why?
|
| Anemia, Sickle Cell | 1 | 2004 | 152 | 0.040 |
Why?
|
| Allosteric Regulation | 2 | 2013 | 71 | 0.040 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2002 | 92 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2022 | 90 | 0.040 |
Why?
|
| Fluorocarbons | 1 | 2002 | 64 | 0.040 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2002 | 62 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 3221 | 0.040 |
Why?
|
| Length of Stay | 1 | 2005 | 860 | 0.040 |
Why?
|
| Albumins | 1 | 2002 | 127 | 0.040 |
Why?
|
| Amino Acid Substitution | 2 | 2013 | 333 | 0.040 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2002 | 102 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2004 | 263 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 2896 | 0.040 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2004 | 338 | 0.040 |
Why?
|
| Survival Rate | 1 | 2005 | 2019 | 0.040 |
Why?
|
| Arginine Vasopressin | 1 | 2001 | 44 | 0.040 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2001 | 38 | 0.040 |
Why?
|
| Renin-Angiotensin System | 1 | 2001 | 87 | 0.040 |
Why?
|
| Neoplasms | 1 | 2016 | 3271 | 0.040 |
Why?
|
| Mitral Valve Prolapse | 1 | 2000 | 18 | 0.040 |
Why?
|
| Injections, Intra-Articular | 1 | 2020 | 36 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2004 | 505 | 0.040 |
Why?
|
| Adolescent | 3 | 2021 | 9948 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2004 | 1434 | 0.030 |
Why?
|
| Contraindications, Procedure | 1 | 2017 | 8 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2015 | 974 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2004 | 1089 | 0.030 |
Why?
|
| Heart Arrest | 1 | 2021 | 315 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2001 | 741 | 0.030 |
Why?
|
| Femur | 1 | 2017 | 107 | 0.030 |
Why?
|
| Animals | 2 | 2013 | 28471 | 0.030 |
Why?
|
| Weight-Bearing | 1 | 2016 | 71 | 0.030 |
Why?
|
| Pregnancy | 1 | 2004 | 3193 | 0.030 |
Why?
|
| Galactose | 1 | 2016 | 28 | 0.030 |
Why?
|
| Spinal Fractures | 1 | 2017 | 103 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2016 | 123 | 0.030 |
Why?
|
| Range of Motion, Articular | 1 | 2016 | 175 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2015 | 76 | 0.030 |
Why?
|
| Drug Inverse Agonism | 1 | 2015 | 3 | 0.030 |
Why?
|
| Scopolamine Derivatives | 1 | 2015 | 4 | 0.030 |
Why?
|
| Tiotropium Bromide | 1 | 2015 | 4 | 0.030 |
Why?
|
| Radioligand Assay | 1 | 2015 | 32 | 0.030 |
Why?
|
| Muscarinic Agonists | 1 | 2015 | 22 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2015 | 160 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2015 | 119 | 0.030 |
Why?
|
| Computer Systems | 1 | 2014 | 63 | 0.030 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2013 | 11 | 0.020 |
Why?
|
| Enteroendocrine Cells | 1 | 2013 | 10 | 0.020 |
Why?
|
| Benzeneacetamides | 1 | 2013 | 13 | 0.020 |
Why?
|
| Lipolysis | 1 | 2013 | 24 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2013 | 118 | 0.020 |
Why?
|
| Cholesterol | 1 | 2015 | 372 | 0.020 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2013 | 63 | 0.020 |
Why?
|
| Larynx | 1 | 2012 | 36 | 0.020 |
Why?
|
| Fourier Analysis | 1 | 2012 | 123 | 0.020 |
Why?
|
| Orexin Receptors | 1 | 2012 | 1 | 0.020 |
Why?
|
| Orexins | 1 | 2012 | 9 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2012 | 67 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 77 | 0.020 |
Why?
|
| Adipocytes | 1 | 2013 | 173 | 0.020 |
Why?
|
| Cell Line | 1 | 2016 | 2478 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 422 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2004 | 2409 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 731 | 0.020 |
Why?
|
| Biosensing Techniques | 1 | 2012 | 82 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2013 | 397 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2014 | 837 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 613 | 0.020 |
Why?
|
| Systole | 1 | 2010 | 81 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2012 | 300 | 0.020 |
Why?
|
| Awareness | 1 | 2010 | 90 | 0.020 |
Why?
|
| Child | 2 | 2015 | 7540 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 1140 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1540 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 514 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2010 | 260 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 7318 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2012 | 1148 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2008 | 134 | 0.020 |
Why?
|
| Rats | 1 | 2013 | 4051 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 406 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2011 | 2845 | 0.010 |
Why?
|
| Body Surface Area | 1 | 2005 | 38 | 0.010 |
Why?
|
| Midwestern United States | 1 | 2005 | 91 | 0.010 |
Why?
|
| Shock | 1 | 2005 | 55 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2348 | 0.010 |
Why?
|
| Heart Valve Diseases | 1 | 2005 | 102 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 303 | 0.010 |
Why?
|
| Prosthesis Failure | 1 | 2004 | 117 | 0.010 |
Why?
|
| Equipment Design | 1 | 2005 | 423 | 0.010 |
Why?
|
| DNA Primers | 1 | 2004 | 530 | 0.010 |
Why?
|
| Age of Onset | 1 | 2004 | 354 | 0.010 |
Why?
|
| Coronary Artery Bypass | 1 | 2005 | 227 | 0.010 |
Why?
|
| Educational Measurement | 1 | 2005 | 240 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 889 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2005 | 524 | 0.010 |
Why?
|
| Pneumonectomy | 1 | 2004 | 219 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 2219 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2004 | 476 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 1879 | 0.010 |
Why?
|
| Students, Medical | 1 | 2005 | 446 | 0.010 |
Why?
|
| Aging | 1 | 2004 | 757 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 12495 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 1270 | 0.010 |
Why?
|